Everest Medicines Signs $61.5 Million Deal for Drug Resistant Antibiotic
publication date: Jan 9, 2019
Everest Medicines, a Shanghai in-licensing company, acquired greater China rights to a multi-drug resistant, gram negative antibiotic from Spero Therapeutics in an agreement worth up to $61.5 million. Everest will pay $2 million upfront and as much as $59.5 million in milestones, plus royalties on sales. It will also have an option on a similar deal for a second Spero MDR IV antibiotic. A two-year-old company, Everest is backed by $50 million in initial financing led by China's C-Bridge Capital. More details....
Stock Symbol: (NSDQ: SPRO)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.